Penserra Capital Management LLC Has $143,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. $DNA

Penserra Capital Management LLC boosted its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 263.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,786 shares of the company’s stock after purchasing an additional 9,271 shares during the quarter. Penserra Capital Management LLC’s holdings in Ginkgo Bioworks were worth $143,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Erste Asset Management GmbH grew its holdings in shares of Ginkgo Bioworks by 123.2% in the 1st quarter. Erste Asset Management GmbH now owns 1,650,000 shares of the company’s stock valued at $9,405,000 after buying an additional 910,668 shares during the period. Millennium Management LLC grew its stake in Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock valued at $8,137,000 after acquiring an additional 757,535 shares during the period. Forbes J M & Co. LLP increased its holdings in shares of Ginkgo Bioworks by 56.0% in the first quarter. Forbes J M & Co. LLP now owns 1,094,564 shares of the company’s stock worth $6,239,000 after acquiring an additional 392,832 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Ginkgo Bioworks by 188.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 439,259 shares of the company’s stock valued at $2,504,000 after purchasing an additional 287,221 shares in the last quarter. Finally, PDT Partners LLC grew its position in shares of Ginkgo Bioworks by 104.0% in the 1st quarter. PDT Partners LLC now owns 385,153 shares of the company’s stock valued at $2,195,000 after purchasing an additional 196,350 shares during the period. 78.63% of the stock is currently owned by institutional investors and hedge funds.

Ginkgo Bioworks Stock Down 4.1%

Ginkgo Bioworks stock opened at $8.02 on Friday. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $17.58. The company’s 50 day moving average price is $12.34 and its two-hundred day moving average price is $10.91. The stock has a market cap of $474.49 million, a P/E ratio of -1.29 and a beta of 1.53.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.21). Ginkgo Bioworks had a negative net margin of 188.00% and a negative return on equity of 51.15%. The business had revenue of $38.84 million for the quarter, compared to analysts’ expectations of $38.95 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Analysts Set New Price Targets

DNA has been the topic of several research analyst reports. BTIG Research raised their target price on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the stock a “sell” rating in a report on Monday, August 25th. Cowen reaffirmed a “buy” rating on shares of Ginkgo Bioworks in a research report on Friday, August 8th. Wall Street Zen cut Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $9.00.

Insider Buying and Selling at Ginkgo Bioworks

In related news, insider Steven P. Coen sold 5,609 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $15.00, for a total transaction of $84,135.00. Following the completion of the transaction, the insider owned 5,503 shares in the company, valued at approximately $82,545. This represents a 50.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.72% of the company’s stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.